Flibanserin is a 5-HT receptor modulator used for the treatment of selected premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA.
- Mechanism
- Curator reviewed
Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.
- Primary indication
- Flibansetrin is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty...Curator reviewed · 2 structured indications
- Formula / weight
- C20H21F3N4O · 390.4021 g/mol (avg)
- First approval
- Canada, 2025 · United States, 2015
- Code names
- BIMT-17 · BIMT-17-BS
- Brand names
Resolves to
PPRRDFIXUUSXRA-UHFFFAOYSA-NSMILESFC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Flibanserin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account